[1]
|
Kataria, P.S., Kendre, P.P. and Patel, A.A. (2017) Ifosfamide-Induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. Journal of Pharmacology and Pharmacotherapeutics, 8, 38-40.
https://doi.org/10.4103/jpp.JPP_182_16
|
[2]
|
Hamilton, J.E., Alexander, M. and Kelleher, F.C. (2020) Ifosfamide-Induced Encephalopathy: The EEG with Frontal Intermittent Delta Activity, and Rapid Resolution with Meth-ylene Blue: A Case Report. Clinical Sarcoma Research, 10, Article No. 25. https://doi.org/10.1186/s13569-020-00147-3
|
[3]
|
Lentz, K.L., Clark, S.M., Ayarza, M., Liu, B., Morgan, K.P., Wind, L.S., et al. (2020) Evaluation of Thiamine for the Prevention of Ifosfamide-Induced Encephalopathy. Journal of Oncology Pharmacy Practice, 26, 406-412.
https://doi.org/10.1177/1078155219859644
|
[4]
|
Sprangers, B. and Lapman, S. (2020) The Growing Pains of Ifosfamide. Clinical Kidney Journal, 13, 500-503.
https://doi.org/10.1093/ckj/sfaa017
|
[5]
|
Matz, E.L. and Hsieh, M.H. (2017) Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-Induced Hemorrhagic Cystitis. Urology, 100, 16-19. https://doi.org/10.1016/j.urology.2016.07.030
|
[6]
|
Martinez, D., Rodelo, J. and Pelaez García, S. (2022) Ifosfamide as a Cause of Fanconi Syndrome. Cureus, 14, e22755.
https://doi.org/10.7759/cureus.22755
|
[7]
|
Tascilar, M., Loos, W.J., Seynaeve, C., Verweij, J. and Sleijfer, S. (2007) The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas. Oncologist, 12, 1351-1360.
https://doi.org/10.1634/theoncologist.12-11-1351
|
[8]
|
Séjourné, A., Noal, S., Boone, M., Bihan, C., Sassier, M., Andrejak, M., et al. (2014) Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant? Case Reports in Oncology, 7, 669-672.
https://doi.org/10.1159/000368184
|
[9]
|
Ajithkumar, T., Parkinson, C., Shamshad, F. and Murray, P. (2007) Ifosfamide Encephalopathy. Clinical Oncology, 19, 108-114. https://doi.org/10.1016/j.clon.2006.11.003
|
[10]
|
Ali Mohamed, D., Semedo, A., Adeyemi, B., Hessissen, L., El Kababri, M., Allali, N., et al. (2021) Reversible Encepah-lopathy Induced by Ifosfamide with Brain Imaging. Global Pediatric Health, 8.
https://doi.org/10.1177/2333794X211030415
|
[11]
|
Modi, J.N. and Cimino, S.K. (2021) Incidence of Ifosfamide Induced Encephalopathy in Patients Receiving Concomitant Fosaprepitant. Journal of Oncology Pharmacy Practice, 27, 1891-1895.
https://doi.org/10.1177/1078155220971794
|
[12]
|
Szabatura, A.H., Cirrone, F., Harris, C., McDonnell, A.M., Feng, Y., Voit, D., et al. (2015) An Assessment of Risk Factors Associated with Ifosfamide-Induced Encephalopathy in a Large Academic Cancer Center. Journal of Oncology Pharmacy Practice, 21, 188-193. https://doi.org/10.1177/1078155214527143
|
[13]
|
Lee Brink, A., Bowe, C. and Dains, J.E. (2020) Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review. Journal of the Advanced Practi-tioner in Oncology, 11, 368-380.
https://doi.org/10.6004/jadpro.2020.11.4.4
|
[14]
|
Rieger, C., Fiegl, M., Tischer, J., Ostermann, H. and Schiel, X. (2004) Incidence and Severity of Ifosfamide-Induced Encephalopathy. Anti-Cancer Drugs, 15, 347-350. https://doi.org/10.1097/00001813-200404000-00006
|
[15]
|
Stern, N., Sakji, I., Defachelles, A.S., Lervat, C., Ryckewaert, T., Marliot, G., et al. (2017) [Incidence and Risk Factors for Ifosfamide-Related Encephalopathy in Sarcoma Patients]. Bulletin du Cancer, 104, 208-212.
https://doi.org/10.1016/j.bulcan.2016.11.007
|
[16]
|
Dufour, C., Grill, J., Sabouraud, P., Behar, C., Munzer, M., Motte, J., et al. (2006) [Ifosfamide Induced Encephalopathy: 15 Observations]. Archives de Pédiatrie, 13, 140-145. https://doi.org/10.1016/j.arcped.2005.10.021
|
[17]
|
Gusdon, A.M., Malani, R. and Chen, X. (2019) Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. Journal of Clinical Neurophysiology, 36, 150-154. https://doi.org/10.1097/WNP.0000000000000539
|
[18]
|
Feyissa, A.M. and Tummala, S. (2014) Ifosfamide Related Encephalopathy: The Need for a Timely EEG Evaluation. Journal of the Neurological Sciences, 336, 109-112. https://doi.org/10.1016/j.jns.2013.10.018
|
[19]
|
Sarbay, H., Demir, Ü.F., Yılmaz, G., Atay, A.A. and Malbora, B. (2021) Ifosfamide Induced Encephalopathy in a Child with Osteosarcoma. Journal of Oncology Pharmacy Practice, 27, 1302-1306.
https://doi.org/10.1177/1078155220963545
|
[20]
|
Lee, E.Q., Arrillaga-Romany, I.C. and Wen, P.Y. (2012) Neuro-logic Complications of Cancer Drug Therapies. Continuum, 18, 355-365. https://doi.org/10.1212/01.CON.0000413663.42798.64
|
[21]
|
Ataseven, E., Göktepe, Ş. and Kantar, M. (2021) Ifosfamide-Related Encephalopathy with Severe Clinical Presentations in Children with Cancer. Journal of Oncology Pharmacy Practice, 27, 2018-2022.
https://doi.org/10.1177/10781552211005533
|
[22]
|
Richards, A., Marshall, H. and McQuary, A. (2011) Evaluation of Methylene Blue, Thiamine, and/or Albumin in the Prevention of Ifosfamide-Related Neurotoxicity. Journal of Oncol-ogy Pharmacy Practice, 17, 372-380.
https://doi.org/10.1177/1078155210385159
|
[23]
|
Abahssain, H., Moukafih, B., Essangri, H., Mrabti, H., Meddah, B., Guessous, F., et al. (2021) Methylene Blue and Ifosfamide-Induced Encephalopathy: Myth or Reality? Journal of Oncology Pharmacy Practice, 27, 143-149.
https://doi.org/10.1177/1078155220971843
|
[24]
|
Liu, Y.L., Tsai, S.H., Chang, F.W. and Yu, M.H. (2010) Ifosfamide-Induced Encephalopathy in Patients with Uterine Sarcoma. Taiwanese Journal of Obstetrics and Gynecology, 49, 77-80.
https://doi.org/10.1016/S1028-4559(10)60014-9
|
[25]
|
Müngen, E., Yaman Bajin, İ., Öz, S., Günbey, C., Anlar, B. and Aydin, B. (2022) Ifosfamide-Induced Encephalopathy with Rapid Response to Thiamine: A Pediatric Case. Journal of Pediatric Hematology/Oncology, 44, 402-404.
https://doi.org/10.1097/MPH.0000000000002473
|
[26]
|
Chain, G., Kalia, M., Kestenbaum, K., Pappas, L., Sech-ser-Perl, A., Campino, G.A., et al. (2022) A Novel Case of Prolonged Ifosfamide Encephalopathy and Long-Term Treatment with Methylene Blue: A Case Report and Review of Literature. BMC Pediatrics, 22, Article No. 76. https://doi.org/10.1186/s12887-022-03144-1
|
[27]
|
Pelgrims, J., De Vos, F., Van den Brande, J., Schrijvers, D., Prové, A. and Vermorken, J.B. (2000) Methylene Blue in the Treatment and Prevention of Ifosfamide-Induced Encepha-lopathy: Report of 12 Cases and a Review of the Literature. British Journal of Cancer, 82, 291-294. https://doi.org/10.1054/bjoc.1999.0917
|
[28]
|
Patel, P.N. (2006) Methylene Blue for Management of Ifosfamide-Induced Encephalopathy. Annals of Pharmacotherapy, 40, 299-303. https://doi.org/10.1345/aph.1G114
|
[29]
|
Gharaibeh, E.Z., Telfah, M., Powers, B.C. and Salacz, M.E. (2019) Hydra-tion, Methylene Blue, and Thiamine as a Prevention Regimen for Ifosfamide-Induced Encephalopathy. Journal of On-cology Pharmacy Practice, 25, 1784-1786.
https://doi.org/10.1177/1078155218808361
|